Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (SNTI) has expanded its leadership team with two strategic appointments. Jay Cross will join as Chief Financial Officer on March 3, 2025, overseeing financial strategy, operations, and investor relations. Faraz Siddiqui joined in January 2025 as Senior Vice President of Technical Operations, managing process development, manufacturing, and supply chain.
CEO Timothy Lu expressed confidence that Cross's financial expertise and Siddiqui's technical operations leadership will support the company's clinical pipeline advancement, particularly for SENTI-202 and SENTI-301A. Cross brings extensive experience from Sonnet BioTherapeutics, where he led a capital campaign raising over $100 million, and from 20 years on Wall Street at firms including Chardan, SAC Capital, and Goldman Sachs.
Siddiqui contributes 27 years of biopharmaceutical experience, particularly in cell therapies, from previous roles at IGM Biosciences, Instil Bio, Kite Pharma, and Genentech, where he specialized in process development and manufacturing operations.
Senti Biosciences (NASDAQ: SNTI) has secured an additional $11.5 million in financing, comprising a $10 million private placement equity investment from Celadon Partners and $1.5 million from a CIRM grant. This additional funding brings the total PIPE financing round to $47.6 million, with participation from notable investors including NEA, Leaps by Bayer, and Nantahala Capital.
The company plans to use the proceeds to fund the development of its SENTI-202 program, manufacturing scale-up, research activities, and general corporate purposes. The funding has extended the company's cash runway guidance into 2026. The CIRM grant payment brings the total received from this source to $6.4 million out of the $8 million total grant announced in June 2024.
Senti Biosciences (SNTI) announced the first patient dosing in a clinical trial of SN301A for hepatocellular carcinoma (HCC) in mainland China, in collaboration with Celest Therapeutics. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of SN301A, a CAR-NK cell therapy utilizing Senti's Gene Circuit platform, in patients with advanced GPC3-expressing HCC across multiple dose cohorts.
Celest is leading the clinical development, operations, and manufacturing in China, with Senti Bio providing technical and strategic input. The study will assess adverse events, dose-limiting toxicities, and efficacy using standard liver cancer response criteria. The collaboration may expand to Hong Kong, Macau, and Taiwan, while Senti Bio retains rights outside these regions.
Senti Biosciences (Nasdaq: SNTI) has announced new employment inducement grants approved by its Compensation Committee on November 26, 2024. The committee granted stock options to three new employees to purchase a total of 49,778 shares of company common stock at an exercise price of $2.11 per share. These grants were made under the company's 2022 Inducement Equity Plan, which was adopted on August 5, 2022, and are in accordance with NASDAQ Listing Rule 5635(c)(4) as inducement material for new employees joining the company.
Senti Biosciences (Nasdaq: SNTI) has secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock. The PIPE financing, led by Celadon Partners with participation from NEA, Leaps by Bayer, and others, is expected to close by December 5, 2024. Investors will receive warrants to purchase up to 25,069,500 common stock shares, subject to stockholder approval. An additional option for $10 million in Preferred Stock was granted to one investor. The proceeds will fund the SENTI-202 program development, manufacturing scale-up, and general corporate purposes.
Senti Biosciences (NASDAQ: SNTI) reported positive initial clinical data from Phase 1 trial of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed/refractory hematologic malignancies including AML. Two out of three patients achieved MRD negative complete remission at the lowest dose level (1.0 billion CAR+ NK cells per dose). Both patients maintain remission after 4+ and 3+ months respectively. The therapy was generally well-tolerated with no dose limiting toxicities. SENTI-202 is designed to selectively target CD33 and/or FLT3-expressing malignancies while sparing healthy bone marrow cells. The trial continues with dose escalation, and additional response and durability data are expected in 2025.
Senti Biosciences (NASDAQ: SNTI) has appointed Fran Schulz to its Board of Directors and as chairperson of the Board's Audit Committee. Schulz, a founding member of Ernst & Young's Life Sciences Practice, brings over 35 years of experience and has been involved in over 100 equity and debt transactions totaling more than $15 billion. She has extensive expertise in finance, strategic planning, and corporate transactions in the life sciences industry. The appointment coincides with Dr. Omid Farokhzad's departure from the Board. Schulz currently serves on the boards of EDAP TMS SA and Menlo College as Audit Committee Chair.
Senti Biosciences (NASDAQ: SNTI) reported Q3 2024 financial results and pipeline updates. The company continues patient dosing in Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies, with initial data expected by end of 2024. Through November 2024, Senti received $4.9M of an $8M CIRM grant. Financial highlights include cash position of $10.5M, R&D expenses of $8.7M (down from $9.1M in Q3 2023), and G&A expenses of $6.2M (down from $9.4M). Net loss was $28.9M or $(6.31) per share. The company's partner Celest plans to initiate SENTI-301A trials in China in Q4 2024.
Senti Biosciences (Nasdaq: SNTI), a biotechnology company specializing in next-generation cell and gene therapies, has announced its participation in two upcoming investor conferences. The company will be present at:
1. H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY, with a pre-recorded presentation available from September 9, 2024, at 7:00 a.m. ET.
2. Chardan's 8th Annual Genetic Medicines Conference in New York, NY, featuring a fireside chat on September 30, 2024, at 5:00 p.m. ET.
Senti Bio's flagship product, SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy, is currently in Phase 1 clinical trials. Investors can access webcasts and replays through the company's website for approximately 90 days following each event.
Senti Biosciences (Nasdaq: SNTI) reported Q2 2024 results and pipeline updates. Key highlights include:
- Ongoing patient dosing in Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies including AML
- Commencement of $8 million CIRM grant for SENTI-202 clinical development
- Plans to initiate pilot trial of SENTI-301A for HCC in China through Celest partnership in Q4 2024
- Q2 2024 financial results: $15.9 million cash, $9.2 million R&D expenses, $4.2 million G&A expenses, $11.2 million net loss
- Completed 1-for-10 reverse stock split to maintain Nasdaq listing compliance
Initial SENTI-202 efficacy data expected by year-end 2024, with durability data in 2025.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
